Ajanta Pharma share news, announcements and annual reports
NSE: AJANTPHARMBSE: 532331Pharmaceuticals & BiotechnologyMid Cap
Ajanta Pharma Limited · Face value ₹2 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed May 2000 on NSE, Jun 2000 on BSE
Last close ₹3,508.80up ₹49.10 (1.42%)BSE ₹3,512.40
Share price at the NSE close on 30 Oct 2026. Previous close ₹3,459.70.
30 Oct: open ₹3,479.00, high ₹3,619.90, low ₹3,460.50
52-week range of traded prices to 30 Oct 2026
₹2,430.00Low, 30 Oct 2025₹3,796.00High, 18 Aug 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹43,846 Cr236th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 34.72
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 9.02
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 1.71%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 27.5%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 30.3%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026.
- 0.02
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 9,52,55826.6% delivered
Ajanta Pharma share news and announcements
812 announcements, routine notices left out, newest first. Page 13 of 17.
Apr 2013
19 Apr · Board meeting
To consider and approve, inter alia : (1) The audited Financial Results for the year ended March 31, 2013 and (2) Recommending dividend, if any, on equity shares of the Company for the Financial year 2012-13.4 Apr · Legal
Spurt in Volume : Substantial increase in trading volumes have been observed in Ajanta Pharma Limited.. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, had written to the company. Ajanta Pharma Limited has vide its letter inter-alia stated, "We would like to state that there is no such information at our end that has a bearing on the operation/performance of the company, including any price-sensitive information, which is not disclosed to the stock exchanges."
Mar 2013
Jan 2013
11 Jan · Board meeting
To consider and approve, inter alia, the Unaudited Financial Results for the third quarter ended December 31, 2012.
Nov 2012
Oct 2012
12 Oct · Board meeting
To consider and approve, inter-alia, the Unaudited Financial Results for the second quarter ended September 30, 2012.
Sep 2012
Aug 2012
Jul 2012
19 Jul · Corporate action
Shareholders of the Company at their Annual General Meeting had approved splitting of shares from a face-value of Rs. 10/- each into two shares of a face-value of Rs. 5/- each. The Board of Directors has fixed the record date for the said corporate action as August 10, 2012.19 Jul · Results
17 Jul · Disclosure of Voting Pattern - Clause 35A
12 Jul · Meeting
At the Annual General Meeting held on July 07, 2012, the shareholders have approved the splitting of shares from face-value of Rs. 10/- into two shares of face-value of Rs. 5/-. At the forthcoming Board Meeting the record date would be fixed by the Board for the purpose of splitting/sub-division of shares.9 Jul · Board meeting
To consider and approve, inter alia, the Unaudited Financial Results for the first quarter ended June 30, 2012.
Jun 2012